EH3A Amarin Corporation Plc Sponsored ADR

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7th, 2025, at 8:00 a.m. ET.

The conference call with management will follow the release of the Company’s first quarter 2025 financial results in the pre-market hours on May 7th.

Conference Call and Webcast Information:

Access to the live call:

Go to the investor relations section of the Company's website at 

Dial in within the United States: 888-506-0062

International dial in: 973-528-0011

Access Code: 253130

Access to replay:

Dial in within the United States: 877-481-4010

International dial in: 919-882-2331

Access Code: 52230

A replay of the call will also be available through the Company's website shortly after the call.

About Amarin

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.

Availability of Other Information About Amarin

Amarin communicates with its investors and the public using the company website () and the investor relations website (), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information

Investor & Media Inquiries:

Mark Marmur

Amarin Corporation plc





EN
28/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amarin Corporation Plc Sponsored ADR

 PRESS RELEASE

Amarin to Report First Quarter 2025 Financial Results and Host Confere...

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s first quarter 2025 financial results in the pre-market hours on May 7th. Confer...

 PRESS RELEASE

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change Action Taken to Maintain Company’s Nasdaq Listing DUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today confirmed that April 11, 2025 will be the effective date for the Company’s previously announced Ratio Change on its American Depositary Shares (“ADS”) -- an action in which the Company will effect a ratio change from one (1) ADS representing one (1) ordinary share to a new ratio of one (1) ADS representing twenty (20) ordinary shares (the "Ratio Change"). The objective...

 PRESS RELEASE

Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Direct...

Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. “On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a ...

 PRESS RELEASE

Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanist...

Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist – Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action and Utility as A Complementary Therapy for Residual Risk Reduction in Combination with Statins in Important Patient Sub-Categories – DUBLIN and BRIDGEWATER, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicos...

 PRESS RELEASE

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (...

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, March...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch